OncoVEX (Head and Neck Cancer) 'Analysis and Forecasts to 2020

Find Industry reports, Company profiles
ReportLinker and Market Statistics
>> Get this Report Now by email!

OncoVEX (Head and Neck Cancer) 'Analysis and Forecasts to 2020
Published on October 2011

Report Summary


Summary

GlobalData's pharmaceuticals report, 'OncoVEX (Head and Neck Cancer) 'Analysis and Forecasts to 2020' provides OncoVEX sales
forecasts for US and EU5. In addition, it covers detailed clinical assessment of the drug, factors impacting drug sales, competitive
landscape, and analysis of sales performance during the forecast period (2019-2020). The report also includes information on Head
and Neck Cancer market. This report is built using data and information sourced from GlobalData's proprietary databases, primary
and secondary research using Company's corporate website, SEC filings, investor presentations and featured press releases, both
from company and industry-specific third party sources, put together with in-house analysis, by GlobalData's team of industry experts.

Note: This is a on-demand report and will be delivered within 7 business days (excluding weekends) of the purchase.

Scope

- Therapy area profile including patient population for the Japan (seven major markets)
- Analysis and review of OncoVEX including historical sales data
- Qualitative and quantitative assessment of market space
- Analysis of the trends, drivers and restraints shaping and defining the markets
- In-depth analysis of OncoVEX including efficacy, safety, pricing, competition and other details which influence its sales potential
- Detailed sales forecast for 2019-2020 for OncoVEX in the Japan

Reasons to buy

- Understand and capitalize by identifying products that are most likely to ensure a robust return
- Stay ahead of competition by understanding the changing competitive landscape
- Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential
- Make more informed business decisions from insightful and in-depth analysis of the drug's performance
- Examine the historical sales performance of a drug in seven major markets
- Obtain sales forecast for currently marketed/pipeline drug for 2011-2020 for all seven major markets

Table of Content

1 Table of contents 2
1.1 List of Tables 3
1.2 List of Figures 3
2 Introduction 4
2.1 Head and Neck Cancer Market 4

OncoVEX (Head and Neck Cancer) 'Analysis and Forecasts to 2020 (From Slideshare) Page 1/6


2.2 Epidemiology 4
2.3 Etiology 7
2.4 GlobalData Analysis and Forecasts Report Guidance 8
3 Head and Neck Cancer Disease: Market Characterization 9
3.1 Head and Neck Cancer Disease Market 9
3.2 Head and Neck Cancer Disease Market Forecasts and CAGR 9
3.3 Drivers for the Head and Neck Cancer Disease Market 10
3.3.1 High Incidence 10
3.3.2 Low Initial Diagnosis Rate 11
3.3.3 Emergence of Targeted Therapies and Vaccines 11
4 Tumor'Node'Metastases (TNM) Classification of Head and Neck Cancer 12
5 OncoVEX (GM-CSF) 20
5.1 Introduction 20
5.2 Mechanism of Action 20
5.3 Clinical Studies 20
5.4 Approval of OncoVEX 21
5.5 Sales Drivers 21
5.5.1 Oncolytic Viral Therapy 21
5.5.2 Potential to be a new standard of care 21
5.5.3 Improved Efficacy 21
5.6 Drug Evaluation 21
Drug Risk Benefit Score 21
5.6.1 Efficacy 22
5.6.2 Safety 22
5.6.3 Compliance 22
5.6.4 Dosing Convenience 22
5.7 Intensity of Competition 22
5.8 Sales forecast 23
5.8.1 Target patient pool of OncoVEX 23
5.8.2 Dosing 23
5.8.3 Market Penetration 24
5.8.4 Annual Cost of Therapy 24
5.8.5 Sales Projections of OncoVEX 24
6 Head and Neck Cancer Market: Appendix 29
6.1 Market Definitions 29
6.2 Abbreviations 29
6.3 Research Methodology 29
6.3.1 Coverage 30
6.3.2 Secondary Research 30
6.3.3 Forecasting 30
6.3.4 Number of Patients Approved to take the Drug 30
6.3.5 Net Penetration of Drug 31
6.3.6 Net Annual Dosing 32
6.3.7 Annual Cost of Therapy 32
6.3.8 Primary Research 32
6.3.9 Expert Panels 32
6.4 Contact Us 33
6.5 Disclaimer 33



6.6 Sources 33

1.1 List of Tables

Table 1: Head and Neck Cancer Incidences & Mortality, 2008-2030 5
Table 2: Head and Neck Cancer, Global, Market Forecasts($bn), 2009'2020 11
Table 3: TNM Classification of the Oral cavity, Larynx, Oropharynx and Hypopharyngeal Cancers 13
Table 4: TNM Classification of the Nasopharyngeal Cancer 18
Table 5: Drug Risk Benefit Score of OncoVEX 23
Table 6: Efficacy Comparison of OncoVEX with its Competitors 24
Table 7: Safety Comparison of OncoVEX with its Competitors 24
Table 8: Head and Neck Cancer, The US,EU-5 , Estimated Sales of OncoVEX ($m), 2019'2020 26
Table 9: Head and Neck Cancer, The US, Estimated Sales of OncoVEX ($m), 2019'2020 26
Table 10: Head and Neck Cancer, The UK, Estimated Sales of OncoVEX ($m), 2019'2020 27
Table 11: Head and Neck Cancer, France, Estimated Sales of OncoVEX ($m), 2019'2020 27
Table 12: Head and Neck Cancer, Germany, Estimated Sales of OncoVEX ($m), 2019'2020 28
Table 13: Head and Neck Cancer, Italy , Estimated Sales of OncoVEX ($m), 2019'2020 29
Table 14: Head and Neck Cancer, Spain , Estimated Sales of OncoVEX ($m), 2019'2020 29

1.2 List of Figures

Figure 1: Top 20 Cancers based on Incidence ' Global, 2008 5
Figure 2: Top 20 Cancers based on Mortality ' Global, 2008 6
Figure 3: Difference between Percentage Distribution of Incidence and Mortality of Top 20 Cancers , 2008 6
Figure 4: Percentage Distribution of various Cancer types in Head and Neck considering US, EU-5 and Japan incidence, 2008 7
Figure 5: Percentage Distribution of various Cancer types in Head and Neck considering Global incidence, 2008 7
Figure 6: Per Capita Cigarette Consumption Curve, the US, 1976-2006 8
Figure 7: Head and Neck Cancer, Global, Market Forecasts ($bn), 2009'2020 10
Figure 8: All Cancer Incidence, Global, 2008-2030 11
Figure 9: Head and Neck Cancer Incidence, Global, 2008-2030 12
Figure 10: Broad Classification of Head and Neck Cancer 13
Figure 11: Detailed TNM Classification of Oral Cavity Cancer 14
Figure 12: Detailed TNM Classification of Laryngeal Cancer 15
Figure 13: Detailed TNM Classification of Oropharyngeal Cancer 16
Figure 14: Detailed TNM Classification of Hypopharyngeal Cancer 17
Figure 15: Detailed TNM Classification of Nasopharyngeal Cancer 19
Figure 16: Classification of Head and Neck Cancer 19
Figure 17: Drug Model Diagram of OncoVEX 24
Figure 18: Head and Neck Cancer, The US, EU'5 , Estimated Sales of OncoVEX ($m) , 2019'2020 25
Figure 19: Head and Neck Cancer, The US, Estimated Sales of OncoVEX ($m), 2019-2020 26
Figure 20: Head and Neck Cancer, The UK , Estimated Sales of OncoVEX ($m), 2019-2020 26
Figure 21: Head and Neck Cancer, France, Estimated Sales of OncoVEX ($m), 2019-2020 27
Figure 22: Head and Neck Cancer, Germany, Estimated Sales of OncoVEX ($m), 2019-2020 28
Figure 23: Head and Neck Cancer, Italy, Estimated Sales of OncoVEX ($m), 2019-2020 28
Figure 24: Head and Neck Cancer, Spain , Estimated Sales of OncoVEX ($m), 2019-2020 29
Figure 25: Head and Neck Cancer, The US, EU'5 , Sales Distribution, 2020 29
Figure 26: GlobalData Methodology 30
Figure 27: : Drug Model Diagram 32



Figure 28: Patients Approved for the Drug 33


Fax Order Form
To place an order via fax simply print this form, fill in the information below and fax the completed form to:
Europe, Middle East and Africa : + 33 4 37 37 15 56
Asia, Oceania and America : + 1 (805) 617 17 93
If you have any questions please visit http://www.reportlinker.com/notify/contact

Order Information
Please verify that the product information is correct and select the format(s) you require.


Product Formats
Please select the product formats and the quantity you require.

1 User License--USD 2 000.00 Quantity: _____

Site License--USD 4 000.00 Quantity: _____

Corporate License--USD 6 000.00 Quantity: _____

Contact Information
Please enter all the information below in BLOCK CAPITALS

Title: Mr Mrs Dr Miss Ms Prof

First Name: _____________________________ Last Name: __________________________________

Email Address: __________________________________________________________________________

Job Title: __________________________________________________________________________

Organization: __________________________________________________________________________

Address: __________________________________________________________________________

City: __________________________________________________________________________

Postal / Zip Code: __________________________________________________________________________

Country: __________________________________________________________________________

Phone Number: __________________________________________________________________________

Fax Number: __________________________________________________________________________


Payment Information
Please indicate the payment method, you would like to use by selecting the appropriate box.

Payment by credit card Card Number: ______________________________________________

Expiry Date __________ / _________

CVV Number _____________________

Card Type (ex: Visa, Amex…) _________________________________

Payment by wire transfer Crédit Mutuel
RIB : 10278 07314 00020257701 89
BIC : CMCIFR2A
IBAN : FR76 1027 8073 1400 0202 5770 189

Payment by check UBIQUICK SAS
16 rue Grenette – 69002 LYON, FRANCE

Customer signature:

Please note that by ordering from Reportlinker you are agreeing to our Terms and Conditions at
http://www.reportlinker.com/index/terms

Please fax this form to:

Europe, Middle East and Africa : + 33 4 37 37 15 56

Asia, Oceania and America : + 1 (805) 617 17 93


OncoVEX (Head and Neck Cancer) 'Analysis and Forecasts to 2020

Recommended

Recommended

More Related Content

More from ReportLinker.com

More from ReportLinker.com (20)

OncoVEX (Head and Neck Cancer) 'Analysis and Forecasts to 2020